Design of Ru(II)-NHC-Diamine Precatalysts Directed by Ligand Cooperation: Applications and Mechanistic Investigations for Asymmetric Hydrogenation
作者:Wei Li、Tobias Wagener、Lars Hellmann、Constantin G. Daniliuc、Christian Mück-Lichtenfeld、Johannes Neugebauer、Frank Glorius
DOI:10.1021/jacs.0c00985
日期:2020.4.15
A modular synthesis of Ru(II)-NHC-diamine complexes from readily available chiral N-heterocyclic carbenes (NHCs) and chiraldiamines is disclosed for the first time. The well-defined Ru(II)-NHC-diamine complexes show unique structure and coordination chemistry including an unusual tridentate coordination effect of 1,2-diphenylethylenediamine. The isolated air- and moisture-stable Ru(II)-NHC-diamine
The present invention relates to compounds of formula (I): useful in treating Alzheimer’s disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
2-Amino- and 2-thio- substituted 1,3-diaminopropanes
申请人:Hom Roy
公开号:US20050267199A1
公开(公告)日:2005-12-01
Disclosed are compounds of the formula:
where variables Q, Z, X, R
15
, R
2
, R
3
, and R
c
are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
The present invention relates to compounds of formula (I):
useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Disclosed are compounds of the formula:
1
where variables Z, X, R
15
, R
2
, R
3
, and R
c
are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.